Actively Recruiting
Study of 3D-printed Custom Applicators for Intracavitary HDR Gynaecological Brachytherapy DISCO
Led by Royal North Shore Hospital · Updated on 2026-02-06
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
R
Royal North Shore Hospital
Lead Sponsor
N
Northern Sydney and Central Coast Area Health Service
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 3D-printed custom applicators for intracavitary high-dose-rate HDR brachytherapy in patients with gynaecological cancers, including endometrial, vaginal, vulva, and recurrent gynaecological cancers. This Phase IIa non-randomised pilot trial aims to assess the feasibility of treating patients using these patient-specific devices, which could offer a more precise and efficient alternative to traditional cylinder-type applicators or custom wax moulds. The study is sponsored by Royal North Shore Hospital and addresses current challenges in applicator design and construction. Participants will receive treatment using 3D-printed custom applicators designed to match optimal planning specifications for HDR brachytherapy. This innovative approach may reduce the time and labor involved in applicator preparation compared to standard wax moulds, while providing a robust and tailored device for therapy. The study focuses on intracavitary brachytherapy procedures for eligible female patients with certain stages of gynaecological cancer. During the study, patients will be closely monitored for treatment success, radiation therapy toxicities, and quality of treatment plans. Researchers will also evaluate the feasibility of MR-only and CT-only planning procedures, optimize applicator design, and assess resource use and costs. Patient experience and acceptability will be measured via questionnaires over a five-year follow-up. Safety and effectiveness outcomes will be carefully tracked to understand the potential benefits and challenges of this new technology.
CONDITIONS
Brief Title
3D Printed Custom Applicators for HDR BT (DISCO)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give informed consent
- Patients indicated for intracavitary brachytherapy
- FIGO stage I-IVA
- ECOG performance status 0-2
- Primary endometrial cancer, primary vaginal cancer, primary vulva cancer, or recurrent gynaecological cancer
You will not qualify if you...
- Pregnancy
- Patients contraindicated for brachytherapy
- History of inflammatory bowel disease, adhesions, or bowel obstruction
- Renal transplant or horseshoe kidney
- Patients with significant lymphovascular space invasion or pelvic sidewall invasion
- Patients requiring interstitial brachytherapy implants
Research Team
M
Marita Morgia, MD
J
Jeremy Booth, PhD QMP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here